Wedbush analyst Liana Moussatos reiterated a Hold rating on Omeros (OMER) today and set a price target of $12.00. The company’s shares closed last Tuesday at $10.54, close to its 52-week low of $8.50.
According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 3.1% and a 45.1% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Catabasis Pharmaceuticals, Global Blood Therapeutics, and Eiger Biopharmaceuticals.
Omeros has an analyst consensus of Moderate Buy, with a price target consensus of $21.25, implying a 108.9% upside from current levels. In a report issued on October 22, Needham also maintained a Hold rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $25.46 and a one-year low of $8.50. Currently, Omeros has an average volume of 1.57M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Omeros Corp. operates as a biopharmaceutical company. It engages in the discovery, development, and commercializes of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.
